Table 4 Summary of study A results—homologous vs heterologous protection to a PCV2a vaccine
Protection Endpoint | Treatment Group (T) | |||
|---|---|---|---|---|
T01—PCV2a challenge control | T02—cPCV2a Vaccine | T03—PCV2b challenge control* | T04—cPCV2a Vaccine* | |
PCV2a challenge (homologous) | PCV2b challenge (heterologous) | |||
Ever positive positive #/total # (%) | ||||
Viremia | 9/10 (90%) | 5/10 (50%) | 9/9 (100%) | 7/10 (70%) |
Fecal Shedding | 9/10 (90%) | 3/10 (30%) | 9/9 (100%) | 3/9 (33.3%) |
Lymphoid Depletion (LD) | 6/10 (60%) | 0/10 (0%) | 6/9 (66.7%) | 4/9 (44.4%) |
Histiocytic Replacement (HR) | 2/10 (20%) | 0/10 (0%) | 6/9 (66.7%) | 2/9 (22.2%) |
Lymphoid Colonization (IHC) | 7/10 (70%) | 4/10 (40%) | 7/9 (77.8%) | 3/9 (33.3%) |